Serum free-light chain removal by high cutoff hemodialysis: Optimizing removal and supportive care

Artificial Organs

Volumn 32, Issue 12, 2008, Pages 910-917

  Hutchison, Colin A ^a,b,c   Harding, Stephen ^d   Mead, Graham ^d   Goehl, Hermann ^e   Storr, Markus ^e   Bradwell, Arthur ^b   Cockwell, Paul ^b,c  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d Binding Site Group Ltd   (United Kingdom)

^e Gambro Dialysatoren GmbH   (Germany)

Author keywords

Clearance; Free light chains; Hemodialysis; High cutoff; Middle molecules; Multiple myeloma

Indexed keywords

BODY FLUIDS; CHAINS; DIALYSIS; HEMODIALYZERS;

CLEARANCE; CLEARANCE RATES; FREE LIGHT CHAINS; HAEMODIALYSIS; HEMODIAFILTRATION; HIGH CUTOFF; MIDDLE MOLECULE; MULTIPLE MYELOMA; RENAL FAILURE; SERUM FREE;

MOLECULES;

ALBUMIN; POLYARYLETHERSULFONE; POLYSULFONE; POVIDONE; UNCLASSIFIED DRUG;

ARTICLE; ARTIFICIAL KIDNEY; CLEARANCE; CLINICAL ARTICLE; HEMODIAFILTRATION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LIGHT CHAIN; MULTIPLE MYELOMA; PRIORITY JOURNAL; ULTRAFILTRATION;

EID: 58149177638     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2008.00653.x     Document Type: Article

References (26)

1. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003 78 : 21 33.
2. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on prognosis. Eur J Haematol 2000 65 : 175 81.
3. Gertz MA. Managing myeloma kidney. Ann Intern Med 2005 143 : 835 7.
4. Blade J, Fernandez-Llama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998 158 : 1889 93.
5. Herrera GA, Joseph L, Gu X, Hough A, Barlogie B. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med 2004 128 : 875 9.
6. Sanders PW, Herrera GA, Kirk KA, Old CW, Galla JH. Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobin light chain deposition. Lab Invest 1991 64 : 527 37.
7. Iggo N, Winearls CG, Davies DR. Editorial: the development of cast nephropathy in multiple myeloma. Q J Med 1997 90 : 653 6.
8. Sanders PW, Brooker BB. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 1992 89 : 630 9.
9. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 1988 33 : 1175 80.
10. Clark WF, Stewart AK, Rock GA, et al. Canadian Apheresis Group: plasma exchange when myeloma presents as acute renal failure: a randomised controlled trial. Ann Intern Med 2005 143 : 777 84.
11. Evans ND, Hattersley J, Hutchison C, et al. Modelling of hemodialysis limiting serum free light chains in patients with renal failure. In : Feng D, Dubois O, Zaytoon J, Carson E, eds., Proceedings of the 6th IFAC Symposium on Modelling and Control of Biomedical Systems. Reims September 20-22. Oxford : Elsevier, 2006 75 80.
12. Cserti C, Haspel R, Stowell C, Dzik W. Light chain removal by plasmapharesis in myeloma-associated renal failure. Transfusion 2007 47 : 511 4.
13. Hutchison CA, Cockwell P, Reid S, et al. Removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007 18 : 886 95.
14. Lee WCR, Uchino S, Fealy N, et al. B2-microglobulin clearance with super high flux hemodialysis: an ex vivo study. Int J Artif Organs 2003 26 : 723 7.
15. Kramer P, Kaufhold G, Grone HJ, et al. Management of anuric intensive-care patients with arteriovenous hemofiltration. Int J Art Organs 1980 3 : 225 30.
16. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive automated immunoassay for immunoglobulin FLCs in serum and urine. Clin Chem 2001 47 : 673 80.
17. Katzmann JA, Clark RJ, Abraham RS, et al. Intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002 48 : 1437 44.
18. Takagi K, Kin K, Itoh Y, Enomoto H, Kawai T. Human alpha 1-microglobulin in various body fluids. J Clin Pathol 1980 33 : 786 91.
19. Ward RA, Greene T, Hartmann B, Samtleben W. Resistance to intercompartmental mass transfer limits β2-microglobulin removal by post-dilution hemodiafiltration. Kidney Int 2006 69 : 1431 7.
20. Ward RA. Protein-leaking membranes for hemodialysis: a new class of membranes in search of an application? J Am Soc Nephrol 2005 16 : 2421 30.
21. Morgera S, Slowinski T, Melzer C, et al. Renal replacement therapy with high-cutoff hemofilters: impact of convection and diffusion on cytokine clearances and protein status. Am J Kidney Dis 2004 43 : 444 53.
22. Kim ST. Characteristics of protein removal in hemodiafiltration. Contrib Nephrol 1994 108 : 23 7.
23. Krieter DH, Lemke HD, Canaud B, Wanner C. Beta(2)-microglobulin removal by extracorporeal renal replacement therapies. Biochim Biophys Acta 2005 1753 : 146 53.
24. Pisitkun T, Eiam-Ong S, Tiranathanagul K, et al. Convective-controlled double high flux hemodiafiltration: a novel blood purification modality. Int J Artif Organs 2004 27 : 195 204.
25. Uchino S, Bellomo R, Morimatsu H, et al. Dialysis: an ex vivo study. ASAIO J 2002 48 : 650 3.
26. Arenholz PG, Winkler RE, Michelsen A, Lang DA, Bowry SK. Dialysis membrane-dependent removal of middle molecules during hemodiafiltration: the beta-2-microglobulin/albumin ratio. Clin Nephrol 2004 62 : 21 8.